By conjugatingselective biomarkers of CEA antibodies to the FSNs, we verified CRCtargeting as evidenced by specific binding to CEA-positive CRC cells.We confirmed that smaller CEA-FSNs have better cellular uptake andbiodegradability than larger CEA-FSNs. This evidence concerns the gene CEACAM5 and colorectal carcinoma.